As I regularly engage with pharma executives and biotech founders, a common theme inevitably arises: why is precision medicine taking so long to become a reality, and is technology to blame
Roche is reported to be considering the sale of its cancer data specialist Flatiron Health, just a few years after it bought the company for $1.9 billion.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
